FEATURED , News

Peter Beitsch, MD/

Targeted Therapy Wins Again #shocker

Patients with a TOPO-2 normal (not overexpressed) breast cancers do not benefit from adriamycin based adjuvant chemotherapy.  Even though we are moving away from using adriamycin, it is still a very effective agent in the right tumors.  This study continues to push forward the concept of targeting of for all breast cancers (probably all cancers period).

http://www.cancertherapyadvisor.com/breast-cancer/breast-cancer-anthracycline-no-survival-benefit-top2a-treatment/article/672236/?DCMP=EMC-CTA_WeeklyHighlights_DMD20170629&cpn=onc_all&hmSubId=&hmEmail=JdPiYjVYOztVXhLI4XxCARpwAZUt9yyvMhkOjt7-LyE1&NID=1336187731&spMailingID=17562559&spUserID=MzQ0NTg1NjM1NDMyS0&spJobID=1042266561&spReportId=MTA0MjI2NjU2MQS2

Leave A Comment